

IN THE CLAIMS:

1. (Canceled).

2. (Canceled).

3. (Canceled)

4. (Canceled).

5. (Canceled).

6. (Canceled).

7. (Currently Amended) A method of treatment of estrogen-deficiency related complaints in female patients that exhibit these complaints while ~~they~~ the female patients are on treatment with a drug which prevents the synthesis of endogenous estrogen, ~~wherein the treatment comprises the administration to~~ comprising:
administering to said female patients ~~of~~ an effective amount of tibolone.

8. (Currently Amended) The method of claim 7, wherein the estrogen-deficiency related complaints ~~comprise~~ are climacteric complaints.

9. (Currently Amended) The method of claim 7 ~~or 8~~, wherein the estrogen-deficiency related complaints ~~comprise~~ are bone loss.

10. (Currently Amended) The method of ~~any one of claims 7-9~~ claim 7, wherein the drug which prevents the synthesis of endogenous estrogen is an aromatase inhibitor.

11. (Currently Amended) The method of ~~any one of the claims 7-10~~ claim 10, wherein the aromatase inhibitor is selected from the group consisting of aminogluthethimide, anastrozole, letrozole, exemestane, and formestane.

12. (Currently Amended) The method of ~~any one of the claims 7-11~~ claim 7, wherein tibolone is administered in a daily dosage of 0.4 to 2.5 mg.